In a report released today, Stephanie Davis from Barclays maintained a Buy rating on Progyny (PGNY – Research Report), with a price target of $48.00. The company’s shares closed yesterday at $32.50.
According to TipRanks, Davis is an analyst with an average return of -6.8% and a 39.93% success rate. Davis covers the Healthcare sector, focusing on stocks such as Laboratory, Quest Diagnostics, and Healthequity.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Progyny with a $47.63 average price target.
Based on Progyny’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $269.94 million and a net profit of $13.47 million. In comparison, last year the company earned a revenue of $214.32 million and had a net profit of $3.41 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Progyny (PGNY) Company Description:
Progyny, Inc. is a medical device company, which engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools. Its services include egg freezing, IVF treatment, surrogacy, podcast, adoption, and Eeva Test. The company was founded on April 03, 2008 and is headquartered in New York, NY.
Read More on PGNY:
- Progyny, Inc. Announces Details for Its First Quarter 2024 Results Report
- Progyny and Fertility Matters Canada Recognize Canadian Fertility Awareness Week to Advocate for Expanded Access to Family Building Care
- Progyny and RESOLVE to Honor National Infertility Awareness Week® with Events Spanning Coast to Coast
- Progyny, Inc. to Present at KeyBanc Life Sciences & MedTech Investor Forum
- Progyny, Inc. to Present at Barclays 26th Annual Global Healthcare Conference
